Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Sematilide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.65 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.62 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.55 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.54 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.54 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | BLM | P54132 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sematilide SCHEMBL9274272 | 0.99 | POLB (0.66) | POLBBLMSMN1; SMN2CYP3A4THRB | |
| Sematilide SCHEMBL161098 | 0.99 | ALDH1A1 (0.67) | POLBBLMSMN1; SMN2CYP3A4THRB | |
| SCHEMBL10642818 | 0.91 | HDAC3 (0.59) | POLBBLMSMN1; SMN2CYP3A4THRB | |
| SCHEMBL10642513 | 0.90 | ALDH1A1 (0.55) | POLBBLMSMN1; SMN2CYP3A4THRB | |
| SCHEMBL10645045 | 0.89 | SMN1; SMN2 (0.57) | POLBBLMSMN1; SMN2CYP3A4THRB | |
| Hydrochloric Acid SCHEMBL10644749 | 0.89 | POLB (0.67) | POLBBLMSMN1; SMN2CYP3A4THRB | |
| SCHEMBL9826682 | 0.89 | ALDH1A1 (0.55) | POLBBLMSMN1; SMN2CYP3A4THRB | |
| SCHEMBL10920006 | 0.89 | KCNH2 (0.60) | POLBBLMSMN1; SMN2CYP3A4THRB | |
| Bromide SCHEMBL10647145 | 0.88 | SMN1; SMN2 (0.56) | POLBBLMSMN1; SMN2CYP3A4THRB | |
| SCHEMBL10645163 | 0.88 | KCNH2 (0.61) | POLBBLMSMN1; SMN2CYP3A4THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-07-25 | — | — | US | disclosed |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2021-09-30 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3258958-B1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RHINOVIRUS INFECTIONS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-05-26 | — | — | EP | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-10995374-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3692989-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | Afecta Pharmaceuticals, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-20200199679-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA | 2020-06-25 | — | — | US | disclosed |
| US-10619209-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-04-14 | — | — | US | disclosed |
| EP-0260901-B1 | BENZENESULPHONAMIDES USEFUL AS ANTI-ARRYTHMIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-03-06 | — | — | EP | disclosed |
| US-4994459-A | Aryloxypropane substituted piperazine derivatives with antiarrhythmic and antifibrillatory activity | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-02-19 | — | — | US | disclosed |
| US-4900841-A | 1-[4-[(methyl-sulfonyl)amino]benzoyl]aziridine | SCHERING A.G. (DE) | 1990-02-13 | — | — | US | disclosed |
| EP-0288423-A1 | Process for the preparation of substituted sulfonamidobenzamides and a novel intermediate thereto | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-10-26 | — | — | EP | disclosed |
| EP-0158775-B1 | SUBSTITUTED SULFONAMIDOBENZAMIDES, ANTIARRYTHMIC AGENTS AND COMPOSITIONS THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-04-20 | — | — | EP | disclosed |
| EP-0260901-A1 | Benzenesulphonamides useful as anti-arrythmic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-03-23 | — | — | EP | disclosed |
| US-4721809-A | Alkylsulfonamido or perfluoroalkylsulfonamido benzenesulfonamides | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-01-26 | — | — | US | disclosed |
| US-4629739-A | Substituted sulfonamidobenzamides and method of treating arrhythmias | SCHERING A.G. (DE) | 1986-12-16 | — | — | US | disclosed |
| EP-0158775-A1 | Substituted sulfonamidobenzamides, antiarrythmic agents and compositions thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-10-23 | — | — | EP | disclosed |
| US-4544654-A | Substituted sulfonamidobenzamides, antiarrhythmic agents and compositions thereof | SCHERING A.G. (DE) | 1985-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10619209-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | KCNH2 1457/4885ACHE 3294/4885HDAC3 1462/4885 |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | KCNH2 1457/4885ACHE 3294/4885HDAC3 1462/4885 |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | KCNH2 1457/4885ACHE 3294/4885HDAC3 1462/4885 |
| US-20200199679-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | KCNH2 1457/4885ACHE 3294/4885HDAC3 1462/4885 |
| US-10995374-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | KCNH2 1457/4885ACHE 3294/4885HDAC3 1462/4885 |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | KCNH2 1457/4885ACHE 3294/4885HDAC3 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.